[{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PBCAR269A","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Dosing of First Patient in Phase 1\/2a Clinical Trial of PBCAR20A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Dosing of First Patient in Phase 1\/2a Clinical Trial of PBCAR269A for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead axes $445M Precision Biosciences Gene Therapy Hep B Pact","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Termination","leadProduct":"HBV gene therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Fast Track Disease Designation from U.S. FDA for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Fast Track Designation from USFDA for PBCAR269A for Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and Servier Expand CART Oncology Development Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"CAR T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$555.0 million","upfrontCash":"$100.0 million","newsHeadline":"Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Precision BioSciences","amount2":0.56000000000000005,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.56000000000000005,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA accepts Precision BioSciences\u2019 IND application for PBCAR19B to treat r\/r non-Hodgkin lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Stealth cell","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Stealth cell","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL-C","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"$1.25 million","newsHeadline":"Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous infusion","sponsorNew":"Precision BioSciences \/ Precision BioSciences","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences and SpringWorks Dose First Patient in Expanded Phase 1\/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision Bio Doses First Patient in Phase 1 Allogeneic CAR T Trial of PBCAR19B Immune Evading Stealth Cell for R\/R Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Anti-CD19 CAR T Cells","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Allogeneic CAR-T Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Precision BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"iECURE","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"PBGENE-PCSK9","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ iECURE","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CAR T Gene Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1\/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PBGENE-PH1","moa":"HO-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PBGENE-PH1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Publication in Molecular Therapy of ARCUS\u00ae In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-T Gene Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PBGENE-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company\u2019s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,475.0 million","upfrontCash":"$75.0 million","newsHeadline":"Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"PBGENE-HbE","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Discovery","graph3":"Precision BioSciences","amount2":1.48,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":1.48,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"PCSK9-specific ARCUS Nuclease Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Imugene","pharmaFlowCategory":"D","amount":"$662.0 million","upfrontCash":"$29.0 million","newsHeadline":"Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0.66000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.66000000000000003,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","amount":"$315.5 million","upfrontCash":"$7.5 million","newsHeadline":"TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.32000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","amount":"$305.5 million","upfrontCash":"$17.5 million","newsHeadline":"Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.31,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"PBGENE-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"PBGENE-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"iECURE","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ECUR-506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ iECURE","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"PBGENE-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1\/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ECUR-506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","amount":"$555.0 million","upfrontCash":"$100.0 million","newsHeadline":"Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Termination","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.56000000000000005,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.56000000000000005,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"PBGENE-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."}]
Find Clinical Drug Pipeline Developments & Deals by Precision BioSciences
Details :
The Company intends to use the net proceeds to support its ongoing research and development, including PBGENE-HBV, designed to eliminate both cccDNA and inactivate HBV DNA. It is being evaluated for the t...
Details :
Precision exercised its option to regain rights for the programs, including its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits.
Details :
ECUR-506, incorporates an ARCUS nuclease vector targeting gene editing in the well-characterized PCSK9 gene locus and a donor vector that inserts the desired functional OTC gene for the treatment of Ornit...
Details :
The net proceeds will be used in the clinical development of PBGENE-HBV, designed to both eliminate cccDNA and inactivate HBV DNA. It is being evaluated for the treatment of Chronic Hepatitis B.
Details :
The net proceeds will be used in the clinical development of PBGENE-HBV, designed to both eliminate cccDNA and inactivate HBV DNA. It is being evaluated for the treatment of Chronic Hepatitis B.
Details :
PBGENE-HBV first and only potentially curative gene editing program that acts as a cccDNA/HBV DNA inhibitor. It is being developed for the treatment of chronic hepatitis B.
Details :
Under the agreement, TG Therapeutics received exclusive worldwide rights to develop and commercialize Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for ...
Details :
Under the agreement, TG Therapeutics will receive exclusive worldwide rights to develop and commercialize Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program ...
Details :
Arcus is a platform designed to develop in vivo gene editing therapies, including gene insertion, excision, and elimination. It has received TGA approval for initiation of Phase 1/2 trial evaluating ECUR-...
Details :
Imugene gains global rights to PBCAR0191 (azercabtagene zapreleucel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing trial for azer-cel in the large B-cell lymphoma...